– Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Infusions Every Three to Five Days – – Approval of Biogen Idec’s Second Innovative Hemophilia Therapy with Prolonged Circulation This Year – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2014-- Today Biogen Idec (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved ELOCTATE™ [Antihemophilic Factor (Recombinant), Fc Fusion Protein] for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with hemophilia A. ELOCTATE is the ...

-Scientific Presentations Showcase Innovative MS Medicines and Experimental Therapies- CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 30, 2014-- Biogen Idec (NASDAQ: BIIB) today announced that more than 60 company-sponsored presentations highlighting key data from its industry-leading portfolio of marketed and investigational multiple sclerosis (MS) therapies are being featured during two neurology conferences, further demonstrating its commitment to meeting the individual needs of MS patients and improving outcomes with research that addresses important efficacy and safety questions. Data are being presented du...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 28, 2014-- Biogen Idec Inc. (NASDAQ: BIIB) announced today that its 2014 Annual Shareholder Meeting will be webcast live on Thursday, June 12, 2014 at 9:00 a.m. ET. To access the live webcast, please visit Biogen Idec’s Investors section at www.biogenidec.com. An archived version of the webcast will be available following the meeting. About Biogen Idec Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorde...

- Global Project Uses Sailing to Empower People Living with Multiple Sclerosis - ZUG, Switzerland--(BUSINESS WIRE)--May 28, 2014-- In celebration of World MS Day and as part of its ongoing mission to support those living with Multiple Sclerosis (MS) globally, Biogen Idec (NASDAQ: BIIB) announced that it has joined the Sailing Sclerosis Foundation’s (SSF) Oceans of Hope project as principal sponsor and official partner. This multi-year, global campaign is designed to use sailing as a means to educate and empower the MS community, changing perceptions of what it means to live with the disease and demonstrating the...

– European Commission Decision on Marketing Authorization Anticipated in 2H of 2014 – – PLEGRIDY May Offer People with MS a Combination of Efficacy, Favorable Safety Profile and Low Frequency Dosing Schedule – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 23, 2014-- Biogen Idec (NASDAQ: BIIB) today received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the marketing authorization of PLEGRIDY™ (peginterferon beta-1a), a pegylated interferon administered subcutaneously for adults with relapsing-remitting multiple sclerosis (RRMS...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 21, 2014-- Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Sanford Bernstein 30th Annual Strategic Decisions Conference. The webcast will be live on Wednesday, May 28, 2014 at 2:00 p.m. ET. To access the live webcast, please visit Biogen Idec’s Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation. About Biogen Idec Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the trea...

– Renowned Neurologist and MS Researcher to Lead Value-Based Medicine Group in New Role – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 12, 2014-- Biogen Idec (NASDAQ: BIIB) today announced that Richard (Rick) A. Rudick, M.D., has joined the company as vice president, Development Sciences, Value-Based Medicine. Dr. Rudick will lead Biogen Idec’s newly created Value-Based Medicine Group, which will focus on using new technology to develop innovative programs and tools to better understand, measure and manage the treatment of multiple sclerosis (MS). These assets are intended to enable physicians and patients to ...

- World Federation of Hemophilia Humanitarian Aid Program to Receive 500 Million International Units Over 5 Years - MELBOURNE, Australia--(BUSINESS WIRE)--May 12, 2014-- Biogen Idec (NASDAQ:BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) today announced their intent to produce one billion international units (IUs) of clotting factor therapy for humanitarian aid programs in the developing world at the World Federation of Hemophilia (WFH) 2014 World Congress. Initially, the companies have committed to donating up to 500 million IUs to the World Federation of Hemophilia over five years to support its effort...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 8, 2014-- Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference. The webcast will be live on Wednesday, May 14, 2014 at 5:00 p.m. PT, 8:00 p.m. ET. To access the live webcast, please visit Biogen Idec’s Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation. About Biogen Idec Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment...

− Additional Data Show Escalation to TYSABRI Following Relapse Improves Clinical Outcomes Compared to Remaining On or Switching Between First-Line Interferon Beta and Glatiramer Acetate − CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 1, 2014-- Biogen Idec (NASDAQ: BIIB) today announced that a post hoc analysis of data from the AFFIRM study shows TYSABRI® (natalizumab) significantly increased the proportion of relapsing-remitting multiple sclerosis (RRMS) patients with confirmed improvement in walking speed (CIWS) relative to placebo at two years. Additional data from observational registry studies show that switching to TYSAB...